Erschienen in:
01.10.2013 | Commentary
On sepsis, troponin and vasopressin: the bitter truth
verfasst von:
Ilse Gradwohl-Matis, Martin W Dünser
Erschienen in:
Critical Care
|
Ausgabe 5/2013
Einloggen, um Zugang zu erhalten
Abstract
One of the rationales for the use of vasopressin in septic shock has been its potential cardioprotective mechanisms. Lower heart rates, higher arterial pressures, and fewer norepinephrine doses during vasopressin therapy were hypothesized to protect the heart from myocardial ischemia. In a prospective sub-study of the VASST (Vasopressin in Septic Shock Trial) project, Mehta and colleagues specifically evaluated this hypothesis but failed to find lower cardiac biomarkers or fewer ischemic electrocardiogram changes in patients receiving vasopressin compared with subjects receiving norepinephrine alone. After recent evidence of a lacking survival benefit, the present study results further challenge the future role of vasopressin as a vasopressor in septic shock.